Saturday 17 October 2026 Export TKNO’s income statement to Excel — free account

Alpha Teknova, Inc.

TKNO Healthcare Drug Manufacturers Specialty & Generic

Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024. In the quarter to June 2026, revenue grew 18.5%, EPS grew 14.3%, free cash flow grew 74.2% and total debt rose 1.43%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

7.08 0.52 −6.84%

Follow TKNO

Alert me

Market cap: $408.0M
P/E: 0.0×
Fwd P/E: −13.3×
Dividend yield: —
F-score: 5/9
Altman Z: 1.83
Beneish M: −3.04
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.14

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	2	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 79.62%

Capital & Financial Ratios $m

Market Cap 408.03

Revenue 43.70

Net Income (16.77)

Free Cash Flow (7.35)

Net Debt (4.22)

Current Ratio 4.49

Debt/Equity 0.21

P/E ratio 0.00

Fwd P/E (13.30)

P/S ratio 8.69

P/B ratio 6.07

Past 5Y EPS Growth —

This Y EPS Growth 5.93%

Next Y EPS Growth 14.09%

Next Y revenue growth 13.52%

Next 5Y EPS Growth 15.57%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 82.83%

10-year low 10-year high

P/B against its own 10 years 97.23%

10-year low 10-year high

EV/Sales against its own 10 years 84.18%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	28	30	21	17
Receivables	4	4	5	5
Inventory	12	7	7	7
Other	—	—	—	—
	46	43	35	31

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	4	—	—
Other	—	—	—	—
	9	11	8	7

Compound Annual Growth %

	10y	5y	3y
Sales	—	5.30%	(0.73%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	32.62%	(11.70%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	11	12	—	—	—
’25	10	10	10	10	41
’24	9	10	10	9	38
’23	9	12	8	8	37
’22	11	12	11	8	41
’21	9	8	9	10	37
’20	6	6	9	10	31

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	0	—	—	—
’25	(4)	(2)	(2)	0	(9)
’24	(7)	(3)	(2)	(1)	(12)
’23	(8)	(4)	(4)	(3)	(19)
’22	(5)	(6)	(8)	(8)	(27)
’21	2	(4)	(5)	(3)	(9)
’20	0	2	(2)	2	3

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(1)	—	—	—
’25	(4)	(2)	(2)	(1)	(10)
’24	(7)	(3)	(2)	(2)	(13)
’23	(12)	(6)	(5)	(3)	(27)
’22	(11)	(17)	(15)	(13)	(56)
’21	(1)	(8)	(9)	(10)	(29)
’20	0	1	(3)	(1)	(3)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.08)	(0.06)	—	—	—
’25	(0.09)	(0.07)	(0.08)	(0.09)	(0.32)
’24	(0.20)	(0.13)	(0.15)	(0.11)	(0.57)
’23	(0.31)	(0.25)	(0.34)	(0.26)	(1.16)
’22	(0.20)	(0.22)	(0.80)	(0.47)	(1.69)
’21	(0.18)	(0.52)	(0.12)	(0.13)	(0.61)
’20	0.01	0.14	0.42	—	0.94

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	16.28	3.02	1.62	1.16	3.60	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	30.89	22.00	6.48	9.72	10.37
People
People	Employees	—	—	—	—	194	237	290	211	173	158
	Revenue/emp, $m	—	—	—	0.00	0.16	0.16	0.14	0.17	0.22	0.26
Income, $m
Income, $m	Revenue	—	—	—	21	31	37	41	37	38	41
	Gross margin, %	—	—	—	37.05	56.73	47.76	42.19	28.07	19.16	33.17
	EBT	—	—	—	(5)	5	(13)	(49)	(37)	(27)	(17)
	EBT margin, %	—	—	—	(21.83)	15.10	(34.25)	(119.24)	(101.07)	(71.09)	(42.45)
	Net income	—	0	—	(1)	4	(10)	(47)	(37)	(27)	(17)
	Depreciation	—	—	—	2	2	3	3	6	7	6
Per share, $
Per share, $	Revenue	—	—	—	0.80	8.70	2.29	1.47	1.15	0.81	0.76
	Earnings	—	—	—	(0.06)	0.99	(0.61)	(1.69)	(1.16)	(0.57)	(0.32)
	Cash flow	—	—	—	0.09	0.70	(0.56)	(0.98)	(0.59)	(0.27)	(0.16)
	Capex	—	—	—	0.00	(1.52)	(1.24)	(1.00)	(0.24)	(0.02)	(0.02)
	Free cash flow	—	—	—	0.09	(0.82)	(1.80)	(1.98)	(0.83)	(0.29)	(0.18)
	Book value	—	—	—	1.86	4.66	8.90	3.56	2.83	1.76	1.29
	Shares, m	—	—	—	26	4	16	28	32	47	53
Valuation, ×
Valuation, ×	P/E	—	—	—	64.73	64.73	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	2.63	2.63	8.93	3.81	3.30	10.34	5.02
	P/B	—	—	—	5.53	5.53	2.30	1.58	1.34	4.74	2.96
	EV/Sales	—	—	—	2.55	2.55	6.88	3.38	2.93	9.89	4.91
	EV/FCF	—	—	—	(19.63)	(19.63)	(8.77)	(2.52)	(4.05)	(27.89)	(20.33)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	2	3	(9)	(27)	(19)	(12)	(9)
	Capex	—	—	—	(3)	(5)	(20)	(28)	(8)	(1)	(1)
	Free cash flow	—	—	—	2	(3)	(29)	(56)	(27)	(13)	(10)
Balance, $m
Balance, $m	Working capital	—	—	—	10	12	93	50	37	32	27
	Total debt	—	—	—	0	—	12	24	13	13	13
	Net debt	—	—	—	(10)	(5)	(76)	(18)	(15)	(17)	(8)
	Shareholders’ equity	—	—	—	49	17	143	100	90	82	69
Returns, %
Returns, %	ROA	—	—	—	(4.92)	1.00	(8.55)	(29.78)	(26.19)	(21.62)	(15.52)
	ROIC	—	—	—	0.00	25.04	(11.11)	(37.92)	(29.71)	(24.95)	(17.52)
	ROE	—	—	—	(9.70)	4.10	(12.26)	(39.05)	(38.73)	(31.02)	(22.83)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AQST Aquestive Therapeutics, Inc.	$509.6M	— (loss-making)	— (loss-making)	+38.15% (above 0%: growing)	n/m	−20.35% (below 0%: shrinking)	70.93%	(59.51%)	Compare
EVO Evotec AG	$504.4M	— (loss-making)	— (loss-making)	−12.98% (below 0%: shrinking)	n/m	−9,727.20% (below 0%: shrinking)	(1.00%)	(77.50%)	Compare
EOLS Evolus, Inc.	$500.0M	— (loss-making)	— (loss-making)	+21.18% (above 0%: growing)	n/m	+84.90% (above 0%: growing)	68.00%	(5.40%)	Compare
TLRY Tilray Brands, Inc.	$474.4M	— (loss-making)	— (loss-making)	+22.74% (above 0%: growing)	n/m	−36.60% (below 0%: shrinking)	30.14%	(9.35%)	Compare
KMDA Kamada Ltd.	$451.7M	20.4×	— (loss-making)	+22.72% (above 0%: growing)	+23.08% (above 0%: growing)	+165.71% (above 0%: growing)	40.91%	17.32%	Compare
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)	Compare
CGC Canopy Growth Corporation	$311.2M	— (loss-making)	— (loss-making)	+12.41% (above 0%: growing)	n/m	−117.60% (below 0%: shrinking)	27.40%	(27.24%)	Compare
ANIK Anika Therapeutics Inc.	$276.9M	— (loss-making)	— (loss-making)	+15.56% (above 0%: growing)	n/m	+61.58% (above 0%: growing)	65.15%	9.06%	Compare
Median of peers	$463.1M	—	—	+21.95%	—	−28.47%	49.74%	(18.29%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Alpha Teknova, Inc. (TKNO) key facts

Strength: Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024.
Alpha Teknova, Inc. (TKNO) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TKNO traded at $7.08, a market capitalization of $408.0 million.
Return on equity was −22.8% and debt-to-equity 0.21.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.83 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.